<DOC>
	<DOC>NCT02097043</DOC>
	<brief_summary>This study is a phase I clinical trial for evaluating the pharmacokinetics and safety/tolerability of DA-7218 in healthy male volunteers.</brief_summary>
	<brief_title>Phase I Clinical Study to Investigate the Pharmacokinetics and Safety/Tolerability of DA-7218 in Healthy Male Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Torezolid phosphate</mesh_term>
	<criteria>Healthy male Korean 1945 years Body weight:5590kg, BMI:18.027.0 Present condition or history of any clinically significant disease Clinical evidence or history of GI disease or history of GI surgery History of hypersensitivities, including drug allergies AST (SGOT) or ALT (SGPT) &gt; 1.5 times the upper normal limit Systolic blood pressure : &lt;100 mmHg or &gt;160 mmHg Diastolic blood pressure : &lt;60 mmHg or &gt;100 mmHg Drug abuse within 2 months, or a positive reaction to an abusive drug or cotinine Taken any ETC or herbal supplement within 2 weeks or any OTC or vitamin supplement within 1 week Participation in and administration of IP of another clinical trial within 2 months Donation of whole blood within 2 months, or blood components within 1 month, or receipt of blood transfusion within 1 month Consumption of more than 21 units of alcohol/week or inability to abstain from drinking during the study period Smoking within 3 months Taking caffeine or grapefruitcontaining products within 3 days Plan to be pregnant, or not to use an appropriate method of contraception</criteria>
	<gender>Male</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>September 2014</verification_date>
</DOC>